Skip to main content
SpringerLink
Log in

Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

We assessed the relationship between changes in PSA and prognosis, as a possible reflection of tumour growth in patients who relapse following primary endocrine therapy.

In 8 patients in whom no therapeutic change was attempted after PSA relapse, the PSA level increased exponentially. Their PSA-DT had a close positive relation-ship to the duration of survival after relapse (r=0.79, p=0.02). In 6 patients who received chemotherapy after relapse, PSA-DT between PSA relapse and initiation of chemotherapy also had a relationship to the duration of survival after relapse (r=0.87, p=0.05).

It appears to be reasonable to conclude from these findings that the PSA-DT value is regarded to be a factor associated with prognosis in cases with an exponential increase in PSA after relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Oesterling, J. E.: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.J. Urol., 145, 907 (1991).

    PubMed  CAS  Google Scholar 

  2. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.N. Engl. J. Med., 317, 909 (1987).

    Article  PubMed  CAS  Google Scholar 

  3. Carter, H. B., Morrell, C. H., Pearson, J. D., Brant, L. J., Plato, C. C., Metter, E. J., Chan, D. W., Fozard, J. L., Walsh, P. C.: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.Cancer Res., 52, 3323 (1992).

    PubMed  CAS  Google Scholar 

  4. Schmid, H. P., McNeal J. E., Stamey, T. A.: Observations on the doubling time of prostate cancer.Cancer, 71, 2031 (1993).

    Article  PubMed  CAS  Google Scholar 

  5. Pollack, A., Zagars, G. K., Kavadi, V. S.: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.Cancer, 74, 670 (1994).

    Article  PubMed  CAS  Google Scholar 

  6. Young, C. Y., Montgomery, B. T., Andrews, P. E., Qui, S. D., Bilhartz, D. L., Tindall, D. J.: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.Cancer Res., 51, 3748 (1991).

    PubMed  CAS  Google Scholar 

  7. Montgomery, B. T., Young, C. Y., Bilhartz, D. L., Andrews, P. E., Prescott, J. L. Thompson, N. F., Tindall, D. J.: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP.Prostate, 21, 63 (1992).

    PubMed  CAS  Google Scholar 

  8. Hanks, G. E., D'Amico, A., Epstein, B. E., Schultheiss, T. E.: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time.Int. J. Radiat. Oncol. Biol. Phys., 27, 125 (1993).

    PubMed  CAS  Google Scholar 

  9. Leo, M. E., Bilhartz, D. L., Bergstrahl, E. J., Oesterling, J. E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?J. Urol., 145, 802 (1991).

    PubMed  CAS  Google Scholar 

  10. Cadeddu, J. A., Pearson, J. D., Partin, A. W., Epstein, J. I., Carter, H. B.: Relationship between changes in prostate-specific antigen and prognosis of prostate cancer.Urology, 42, 383 (1993).

    Article  PubMed  CAS  Google Scholar 

  11. D'Amico, A. V., Hanks, G. E.: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer.Cancer, 72, 2638 (1993).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Yamagata University School of Medicine, Yamagata, Japan

    Y. Kubota, H. Yanai, I. Sasagawa, H. Suzuki & T. Nakada

  2. Department of Urology, Yamagata Prefectural Central Hospital, Yamagata, Japan

    O. Sugano

Authors
  1. Y. Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Yanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Sasagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Nakada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Sugano
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kubota, Y., Yanai, H., Sasagawa, I. et al. Prostate-specific antigen in patients with relapsed prostate cancer following endocrine treatment. International Urology and Nephrology 28, 349–355 (1996). https://doi.org/10.1007/BF02550497

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02550497

Keywords

Search

Navigation